Cart
sales@molnova.com
Ganoderenic acid H
CAS No. 120462-48-8
Ganoderenic acid H( —— )
Catalog No. M31130 CAS No. 120462-48-8
Ganoderenic acid H is one compound of triterpenoids isolated from Ganoderma lucidum, triterpenoids exhibit a broad spectrum of anti-cancer properties, including anti-proliferative, anti-metastatic and anti-angiogenic activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 711 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGanoderenic acid H
-
NoteResearch use only, not for human use.
-
Brief DescriptionGanoderenic acid H is one compound of triterpenoids isolated from Ganoderma lucidum, triterpenoids exhibit a broad spectrum of anti-cancer properties, including anti-proliferative, anti-metastatic and anti-angiogenic activities.
-
DescriptionGanoderenic acid H is one compound of triterpenoids isolated from Ganoderma lucidum, triterpenoids exhibit a broad spectrum of anti-cancer properties, including anti-proliferative, anti-metastatic and anti-angiogenic activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number120462-48-8
-
Formula Weight512.64
-
Molecular FormulaC30H40O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
(20R)-Ginsenoside Rh...
20S, 20R ginsenoside-Rh1 can inhibit the thrombin-induced conversion of fibrinogen to fibrin.
-
AKBA
3-O-Acetyl-11-keto-beta-boswellic acid inhibits 5-lipoxygenase product formation with an IC(5) of 1.5 m muM.
-
N6F11
N6F11 is a novel, selective and potent inducer of ferroptosis with anticancer and antitumour activity that promotes GPX4 degradation by binding to TRIM25 in cancer cells.
